{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T10:19:30Z","timestamp":1695550770842},"reference-count":20,"publisher":"American Society for Microbiology","issue":"23","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Virol"],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Estimates for the risk of transmitting variant Creutzfeldt-Jakob disease (vCJD) via blood transfusion have relied largely on data from rodent experiments, but the relationship between dose (amount of infected blood) and response (vCJD infection) has never been well quantified. The goal of this study was to develop a dose-response model based on nonhuman primate data to better estimate the likelihood of transfusion-transmitted vCJD (TTvCJD) in humans. Our model used dose-response data from nonhuman primates inoculated intracerebrally (i.c.) with brain tissues of patients with sporadic and familial CJD. We analyzed the data statistically by using a beta-Poisson dose-response model. We further adjusted model parameters to account for the differences in infectivity between blood and brain tissue and in transmission efficiency between intravenous (i.v.) and i.c. routes to estimate dose-dependent TTvCJD infection. The model estimates a mean infection rate of 76% among recipients who receive one unit of whole blood collected from an infected donor near the end of the incubation period. The nonhuman primate model provides estimates that are more consistent with those derived from a risk analysis of transfused nonleukoreduced red blood cells in the United Kingdom than prior estimates based on rodent models.<\/jats:p>\n          <jats:p>\n            <jats:bold>IMPORTANCE<\/jats:bold>\n            TTvCJD was recently identified as one of three emerging infectious diseases posing the greatest immediate threat to the safety of the blood supply. Cases of TTvCJD were reported in recipients of nonleukoreduced red blood cells and coagulation factor VIII manufactured from blood of United Kingdom donors. As the quantity of abnormal prions (the causative agent of TTvCJD) varies significantly in different blood components and products, it is necessary to quantify the dose-response relationship for a wide range of doses for the vCJD agent in transfused blood and plasma derivatives. In this paper, we suggest the first mechanistic dose-response model for TTvCJD infection based on data from experiments with nonhuman primates. This new model may improve estimates of the possible risk to humans.\n          <\/jats:p>","DOI":"10.1128\/jvi.01805-14","type":"journal-article","created":{"date-parts":[[2014,9,18]],"date-time":"2014-09-18T07:09:09Z","timestamp":1411024149000},"page":"13732-13736","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":4,"title":["Development of Dose-Response Models of Creutzfeldt-Jakob Disease Infection in Nonhuman Primates for Assessing the Risk of Transfusion-Transmitted Variant Creutzfeldt-Jakob Disease"],"prefix":"10.1128","volume":"88","author":[{"given":"Yin","family":"Huang","sequence":"first","affiliation":[{"name":"Office of Biostatistics and Epidemiology, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Gregori","sequence":"additional","affiliation":[{"name":"Office of Blood Research and Review, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven A.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Office of Biostatistics and Epidemiology, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Asher","sequence":"additional","affiliation":[{"name":"Office of Blood Research and Review, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Yang","sequence":"additional","affiliation":[{"name":"Office of Biostatistics and Epidemiology, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)91412-9"},{"key":"e_1_3_2_3_2","unstructured":"The UK National Creutzfeldt-Jakob Disease Research & Surveillance Unit and the UK Blood Services. 12 February 2013. Transfusion medicine epidemiology review (TMER). http:\/\/www.cjd.ed.ac.uk\/TMER\/TMER.htm."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410350504"},{"key":"e_1_3_2_5_2","volume-title":"Quantitative microbial risk assessment","author":"Haas CN","year":"1999","unstructured":"HaasCN RoseJB GerbaCP. 1999. Quantitative microbial risk assessment. John Wiley & Sons, New York, NY."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2001.130353"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05403-4"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2008.01.028"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.1465"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature03989"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1999.39111169.x"},{"key":"e_1_3_2_12_2","volume-title":"Draft quantitative risk assessment of vCJD risk potentially associated with the use of human plasma-derived factor VIII manufactured under United States (US) license from plasma collected in the US","author":"FDA","year":"2006","unstructured":"FDA. 2006. Draft quantitative risk assessment of vCJD risk potentially associated with the use of human plasma-derived factor VIII manufactured under United States (US) license from plasma collected in the US. US Food and Drug Administration, Washington, DC. http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/SafetyAvailability\/BloodSafety\/UCM095104.pdf. Accessed 4 January 2013."},{"key":"e_1_3_2_13_2","volume-title":"Risk assessment of exposure to vCJD infectivity in blood and blood products (updated May 2006)","author":"United Kingdom Department of Health","year":"2002","unstructured":"United Kingdom Department of Health. 2002. Risk assessment of exposure to vCJD infectivity in blood and blood products (updated May 2006). United Kingdom Department of Health, London, United Kingdom."},{"key":"e_1_3_2_14_2","volume-title":"Evaluation of the potential for bovine spongiform encephalopathy in the United States","author":"Harvard Center for Risk Analysis, Harvard School of Public Health","year":"2003","unstructured":"Harvard Center for Risk Analysis, Harvard School of Public Health. 2003. Evaluation of the potential for bovine spongiform encephalopathy in the United States. Harvard School of Public Health, Boston MA."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1833677100"},{"key":"e_1_3_2_16_2","volume-title":"Doctoral dissertation","author":"Huang Y","year":"2010","unstructured":"HuangY. 2010. Incorporating time to response into dose-response models used in quantitative microbial risk assessment. Doctoral dissertation. Drexel University, Philadelphia, PA."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-79-3-609"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03199.x"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1998.38998408999.x"},{"key":"e_1_3_2_20_2","volume-title":"vCJD and transfusion of blood components: an updated risk assessment","author":"Bennett P","year":"2013","unstructured":"BennettP DaraktchievM. 2013. vCJD and transfusion of blood components: an updated risk assessment. United Kingdom Department of Health, London, United Kingdom."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0066352"}],"container-title":["Journal of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JVI.01805-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JVI.01805-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T21:42:54Z","timestamp":1646430174000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JVI.01805-14"}},"subtitle":[],"editor":[{"given":"B. W.","family":"Caughey","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":20,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["10.1128\/JVI.01805-14"],"URL":"https:\/\/doi.org\/10.1128\/jvi.01805-14","relation":{},"ISSN":["0022-538X","1098-5514"],"issn-type":[{"value":"0022-538X","type":"print"},{"value":"1098-5514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"2014-06-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-09-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-10-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}